Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2007 Oct 17;2007(4):CD003190.
doi: 10.1002/14651858.CD003190.pub4.

Anticholinergic drugs versus other medications for overactive bladder syndrome in adults

C Roxburgh  1 , J Cook, N Dublin
Affiliations
Meta-Analysis

Anticholinergic drugs versus other medications for overactive bladder syndrome in adults

C Roxburgh et al. Cochrane Database Syst Rev. .

Abstract

Background: Overactive bladder syndrome is defined as "urgency with or without urge incontinence, usually with frequency and nocturia". It is a common condition with significant economic and quality of life implications. While the condition's pathophysiology remains to be fully elucidated, pharmacotherapy is the main treatment option. Despite uncertainty as to drug treatment of choice, anticholinergics are increasingly being used in primary and secondary care settings. This review compares anticholinergic drugs with other types or classes of drugs for treating overactive bladder syndromes.

Objectives: To compare anticholinergic drugs with other types or classes of drugs for treating overactive bladder symptoms.

Search strategy: We searched the Cochrane Incontinence Group Specialised Trials Register (searched 20 December 2006) and the reference lists of relevant articles. No language or other limits were imposed.

Selection criteria: All randomised and quasi-randomised controlled trials comparing anticholinergic drugs with other drugs for the treatment of overactive bladder symptoms. At least one arm of the study used an anticholinergic drug and at least one other arm used a non-anticholinergic drug.

Data collection and analysis: Two reviewers assessed the identified studies for eligibility and methodological quality and independently extracted data from the included studies. Data analysis was performed using RevMan software (version 4.2.8).

Main results: Twelve trials were included in the review. There were seven crossover trials and five parallel group studies. For the comparisons between anticholinergic drugs with tricyclic antidepressants, alpha adrenergic agonists, afferent nerve inhibitors, and calcium channel blocker a single trial was identified for each. Nine trials compared flavoxate with anticholinergics. There was no evidence of a difference in cure rates between anticholinergics and flavoxate. Adverse effects were more frequent in anticholinergic groups versus flavoxate groups (RR 2.28 95% CI 1.45 to 3.56). There was no strong evidence to favour either anticholinergic drugs or the comparators.

Authors' conclusions: Many of the drugs considered in trials in this review are no longer used in clinical practice (and this includes the most commonly tested - flavoxate). There is inadequate evidence as to determine whether any of the available drugs are better or worse than anticholinergic medications. Larger randomised controlled trials in clinical settings are required to further establish the role of these medications in the management of overactive bladder syndrome.

PubMed Disclaimer

Conflict of interest statement

None.

Figures

2.2
2.2. Analysis
Comparison 2 Anticholinergics versus afferent nerve inhibitors, Outcome 2 Number not cured after treatment.
2.4
2.4. Analysis
Comparison 2 Anticholinergics versus afferent nerve inhibitors, Outcome 4 Number not improved after treatment.
2.10
2.10. Analysis
Comparison 2 Anticholinergics versus afferent nerve inhibitors, Outcome 10 Improvement in urodynamic diagosed detrusor overactivity.
2.12
2.12. Analysis
Comparison 2 Anticholinergics versus afferent nerve inhibitors, Outcome 12 Number of micturitions per 24hours.
5.2
5.2. Analysis
Comparison 5 Anticholinergics versus Flavoxate, Outcome 2 Number not cured after treatment.
5.4
5.4. Analysis
Comparison 5 Anticholinergics versus Flavoxate, Outcome 4 Number not improved after treatment.
5.6
5.6. Analysis
Comparison 5 Anticholinergics versus Flavoxate, Outcome 6 Number with nocturia after treatment.
5.14
5.14. Analysis
Comparison 5 Anticholinergics versus Flavoxate, Outcome 14 Number experiencing adverse effects.
5.15
5.15. Analysis
Comparison 5 Anticholinergics versus Flavoxate, Outcome 15 Number withdrawing from treatment.
6.14
6.14. Analysis
Comparison 6 Anticholinergics versus other medications, Outcome 14 Number experiencing adverse effects.
See this image and copyright information in PMC

Update of

References

References to studies included in this review

Cardozo 1979 {published data only}
    1. Cardozo LD, Stanton SL. An objective comparison of the effects of parenterally administered drugs in patients suffering from detrusor instability. Journal of Urology 1979;122:58‐9. [Ref ID 2627] - PubMed
Enzelsberger 1991 {published data only}
    1. Enzelsberger H, Schatten C, Kurz C. Comparison of emepronium bromide with intravesical administration of lidocaine gel in women with urge incontinance [Vergleeich von Emeproniumbromid mit intravesikal appliziertem Lidocain‐gel bei Frauen mit Urge‐Inkontinenz]. Geburtschilfe und Frauenheilkunde 1991;51(1):54‐7. [Ref ID 272] - PubMed
Frohlich 1998 {published data only}
    1. Frohlich G, Burmeister S, Weidermann A, Bulitta M. Intravesical instillation of trospium chloride, oxybutinin and verapamil for relaxation of the bladder detrusor muscle. A placebo contolled randomized clinical test. [Intravesikal instillation von trospiumchlorid, oxybutinin und verapamil zur relaxation des harnblasen‐detrusors. Ein placebo‐kontrollierte, randomisierte klinische prufung]. Arzneimittelforschung 1998;48(5):486‐91. [Ref ID 7874] - PubMed
Gaudenz 1978 {published data only}
    1. Gaudenz R, Weil A. Motor urge incontinence: diagnosis and treatment. Urologia Internationalis 1980;35(1):1‐12. [MEDLINE: ] - PubMed
Herbst 1970 {published data only}
    1. Herbst WP. Double blind comparison of flavoxate and propantheline as urologic antispasmodics. American Journal of Clinical Research 1970;1:65‐7. [Ref ID: 5154]
Meyhoff 1981 {published data only}
    1. Meyhoff HH, Gerstenberg TC, Nordling J. Placebo ‐ the drug of choice in female motor urge incontinence?. British Journal of Urology 1983;55(1):34‐7. [Ref ID:685] - PubMed
Milani 1993 {published data only}
    1. Milani R, Scalambrino S, Milia R, Sambruni I, Riva D, Pulici L, et al. Double blind crossover comparison of flavoxate and oxybutynin in women affected by urinary urge syndrome. International Urogynaecology Journal 1993;4:3‐8. [Ref ID: 6169]
Riva 1989 {published data only}
    1. Riva D, Vigano R, Azzolini E, Colli E, Sartanj A, Scatigna M. A randomised, double‐blind, crossover trial on the effecacy and tolerance of falvoxate and oxybutynin in the treatment of urge incontinence. Proceedings of the International Continence Society (ICS), 13th Annual Meeting; 1989 Sept 7‐9; Ljubljiana, Slovenia. 1989:218. [Ref ID: 12036]
Serels 1998 {published data only}
    1. Serels S, Stein M. Prospective study comparing hyoscyamine, doxazosin and combination therapy for the treatment of urgency and frequency in women. Neurourology & Urodynamics 1998;17(1):31‐6. [MEDLINE: ] - PubMed
Stanton 1973 {published data only}
    1. Stanton SL. A comparison of emepronium bromide and flavoxate hydrochloride in the treatment of urinary incontinence. Journal of Urology 1973;110(5):529‐32. [Ref ID: 2649] - PubMed
Takayasu 1990 {published data only}
    1. Takayasu H, Ueno A, Tsuchida S, Koiso K, Kurita T, Kawabe K, et al. Clinical evaluation of propiverine hydrochloride (P‐4) for the treatment of urinary frequency ‐ A double‐blind controlled study using flavoxate hydrochloide. Nishinihon Journal of Urology 1990;52(2):248‐58. [Ref ID: 12897]
Wehnert 1989 {published data only}
    1. Wehnert J, Sage S. Comparative studies of the effect of mictonorm (propiverin hydrochloride) and Spasuret (flavoxate hydrochloride) on the bladder detrusor muscle (GERMAN) [Vergleichende Untersuchungen zur Wirkung von Mictonorm (Propiverin hydrochlorid) und Spasuret (flavoxat hydrochlorid) auf den Detrusor vesicae]. Zeitschrift Fur Urologie und Nephrologie 1989;82(5):259‐63. [Ref ID:408] - PubMed

References to studies excluded from this review

Aagard 1983 {published data only}
    1. Aagaard J, Reuther K, Stimpel H. A comparision between the combination emepronium bromide/flavoxate and emepronium bromide in the treatment of detrusor instability. Urologia Internationalis 1983;38(3):191‐2. - PubMed
Andersen 1988 {published data only}
    1. Andersen JR, Lose G, Norgaard M, Stimpel H, Andersen JT. Terodiline, Emepronium bromide or placebo for treatment of female detrusor overactivity? A randomized, double ‐blind cross‐over study. British Journal of Urology 1988;61(4):310‐3. - PubMed
Athanasopoulos 2002 {published data only}
    1. Athanasopoulos A, Gyftopoulos K, Giannitsas K, Fisfis I, Perimenis P, Barbalias G. Combination treatment with an a‐blocker plus an anticholinergic improves quality of life in patients with bladder outflet obstruction. A prospective, randomized, controlled study (Abstract). Neurourology and Urodynamics 2002;21(4):308‐9.
Barnick 1991 {published data only}
    1. Barnick CGW, Cutner A, Cardozo LD. Detrusor instability: a double blind, dose titrated, cross‐over study of Oxybutinin vesus Terodiline. Proceedings of the International Continence Society (ICS), 21st Annual Meeting; 1991 Oct 10‐12; Hannover, Federal Republic of Germany. 1991:181‐2.
Beisland 1985 {published data only}
    1. Beisland HO, Fossberg E. The effects of terodiline and melardazine on sever motor urge incontinence in geriatric patients. Journal of American Geriatric Society 1985;33(1):29‐32. - PubMed
Bradley 1970 {published data only}
    1. Bradley DV, Cazort RJ. Relief of bladder spasm by Flavoxate. A comparative study. Journal of Clinical Pharmacology 1970;10(1):65‐8. - PubMed
Clark 1996 {published data only}
    1. Clarke B. Anticholinergic medication for the unstable bladder: Prospective trials of imipramine/propantheline versus penthienate and oxybutinin versus penthienate. International Urogynecology Journal of Pelivic Floor Dysfunction 1996;7:191‐5. - PubMed
Ekstrom 1990 {published data only}
    1. Ekstrom B, Andersson KE, Mattiasson A. Intravesical administration of drugs in patients with detrusor hyperactivity. Neurourology and Urodynamics 1990;9(4):340.
El Bahnasawy 2002 {published data only}
    1. Bahnasawy MS, Shaaban HS, Gomha MA, Nabeeh A. Management of noctural incontinence in orthotopic ileal reservoirs using oxybutinin versus verapamil: A proscpective randomised crossover study. Journal of Urology 2002;167:86.
Gruneberger 1984 {published data only}
    1. Gruneberger A. Treatment of motor urge incontinence with clenbuterol and flavoxate hydrochloride. British Journal of Obstetrics and Gynaecology 1984;91(3):275‐8. - PubMed
Homma 1997 {published data only}
    1. Homma Y, Aso Y, Kawabe K, Kunamoto Y, Tsuchida M, et al. Randomized double blind study to compare clinical efficacy of temeverine and propiverine for unstable bladder and detrusor hyperreflexia. Neurourology and Urodynamics 1997;16(5):345‐6.
Lee 2005 {published data only}
    1. Lee KS, Choo MS, Kim DY, Kim JC, Kim HJ, Min KS, et al. Combination treatment with propiveriene hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and coexisting benign prostatic obstruction: a prospective randomised controlled multicentre study. Journal of Urology 1005;174:1334‐8. - PubMed
    1. Lee KS, Kim DY, Kim JC, Kim HJ, Min KS, Park WH, et al. Combination treatment with propiverine hydrochloride and doxazosin GITS in men with overactive bladder coexisting benign prostatic obstruction: a prospective, randomized, controlled, multicentre study (ABSTRACT). Proceedings from the International Continence Society (34th Annual Meeting) and the International Urogynaecological Association; 2004 Aug 23‐27; Paris. 2004; Vol. 207.
Lukkarinen 1987 {published data only}
    1. Lukkarinen O, Grohn P, Wilen‐Rosenquvist G, Juusela H, Sotarauta M, Lehtonen T. A controlled, double blind, cross over study of terodiline in motor urge incontinence. Annales Chirurgiae et Gynaecologiae 1987;76(2):121‐32. - PubMed
Robinson 1983 {published data only}
    1. Robinson JM, Brocklehurst JC. Emepronium bromide and flavoxate hydrochloride in the treatment of urinary incontinence associated with detrusor instability in elderly women. British Journal of Urology 1983;55(4):371‐6. - PubMed
Sole 1984 {published data only}
    1. Sole GM, Arkell DG. A symptomatic and cystomtric comparison of terodiline with emepronium in the treatment of women with frequency, urgency and incontinence. Scandanavian Journal of Urology and Nephrology Supplementum 1984;87:55‐7. - PubMed
Tammela 1999 {published data only}
    1. Tammela TLJ, Mattiasson A, Chapple CR, Moller B, Bakke A, Happonen P. Short term efficacy and safety of temeverine in the treatment of bladder overactivity. A randomized clinical trial in man and women. Nerourology and Urodynamics 2000;18(4):334‐5.
Zeegers 1987 {published data only}
    1. Zeegers A, Keisswetter H, Kramer A, Jonas U. Conservative therapy of urgency and urge incontinence: a double blind clinical trial of flavoxate hydrochloride, oxybutinin chloride, emepronium bromide and placebo [Medicamenteuze behandeling van overmatige mictiedrang: Dubbel‐blind onderzoek van Cetiprin, Dridase, Urispas en placebo]. World Journal of Urology 1987;5(1):57‐61. [Ref ID: 5158]

References to ongoing studies

Shaw {unpublished data only}
    1. Leistershire MRC Incontinence Study. Ongoing study 1999.

Additional references

2nd ICI 2001
    1. Abrams P, Cardozo L, Khoury S, Wein A. Incontinence: 2nd International Consultation for Incontinence. Plymouth: Health Publication Ltd, 2001:481.
Abrams 1988
    1. Abrams PH, Blaivas JG, Stanton SL, Andersen JT. Standardisation of terminology of lower urinary tract function. Neurourology & Urodynamics 1988;7(5):403‐27. - PubMed
Abrams 2002
    1. Abrams P, Cardoza L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardisation of terminology of lower urinary tract function: Report from the standardisation sub‐committee of the International Continence Society. Neurology & Urodynamics 2002;21(2):167‐78. - PubMed
Abrams 2003
    1. Abrams P, Amarenco G, Bakke A, Bukzynski A, Castro‐Diaz D, et al. Tamsulosin: Efficacy and safety in patients with neurogenic lower urinary tract dysfunction due to suprasacral spinal cord injury. Journal of Urology 2003;170:1242‐51. - PubMed
Alhasso 2006
    1. Alhasso AA, McKinley J, Patrick K, Stewart L. Anticholinergic drugs versus non‐drug therapies for overactive bladder syndrome in adults. Cochrane Database of Systematic Reviews 2006, Issue 4. [Art. No.: CD003193. DOI: 10.1002/14651858.CD003193.pub3] - PubMed
Andersson 2000
    1. Andersson KE. Treatment of overactive bladder: other drug mechanisms. Urology 2000;55 (Suppl 5A):51‐7. - PubMed
Andersson 2002
    1. Andersson, KE. Potential benefits of Muscarinic M3 receptor selectivity. European Urology Supplements 2002;1(4):23‐8.
Berghmans 2004
    1. Berghmans B, Bo K, Hendriks E, Kempen M, die Bie R. Electrical stimulation with non‐implanted electrodes for urinary incontinence in adults. Cochrane Database of Systematic Reviews 2004, Issue 3. - PMC - PubMed
Castleden 1986
    1. Castleden CM, Duffin HM, Gulati RS. Double‐blind study of imipramine and placebo for incontinence due to bladder instability. Age Ageing 1986;15:299. - PubMed
Chapple 1990
    1. Chapple CR, Parkhouse H, Gardener C, et al. Double‐blind, placebo‐controlled, crossover study of flavoxate in the treatment of idiopathic detrusor instability. British Journal of Urology 1990;66:491. - PubMed
Cruz 1997
    1. Cruz F, Guimaraes M, Silva C, et al. Suppression of bladder hyperreflexia by intravesical instillation of resiniferatoxin. Lancet 1997;350:640. - PubMed
Dahm 1995
    1. Dahm TL, Ostri P, Kristensen JK, et al. Flavoxate treatment of micturiton disorders accompanying benign prostatic hypertrophy: a double‐blind, placebo‐controlled, multicentre investigation. Urology International 1995;55:205. - PubMed
de Groat 1997
    1. Groat WC. A neurologic basis for the overactive bladder. Urology 1997;50 (6A Suppl):36‐52. - PubMed
Dmochowski 2007
    1. Dmochowski R, Sand PK. Botulinum toxin A in the overactive bladder: current status and future directions. BJU International 2007;99(2):247‐62. - PubMed
Duthie 2007
    1. Duthie J, Wilson DI, Herbison GP, Wilson D. Botulinum toxin injections for adults with overactive bladder syndrome. Cochrane Database of Systematic Reviews 2007, Issue 3. [Art. No.: CD005493. DOI: 10.1002/14651858.CD005493] - PubMed
Eri 1995
    1. Eri LM, Tveter KJ. Alpha blockade in the treatment of syptomatic benign prostatic hyperplasia. Journal of Urology 1995;154:923. - PubMed
Hay‐Smith 2005
    1. Hay‐Smith J, Herbison P, Ellis G, Morris A. Which anticholinergic drug for overactive bladder symptoms in adults. Cochrane Database of Systematic Reviews 2005, Issue 3. [Art. No.: CD005429. DOI: 10.1002/14651858.CD005429] - PubMed
Herbison 2003
    1. Herbison P, Arnold E. Neuromodulation with implanted electrodes for urinary storage and voiding dysfunction in adults. Cochrane Database of Systematic Reviews 2003, Issue 2. [Art. No.: CD004202. DOI: 10.1002/14651858.CD004202] - PubMed
Higgins 2006
    1. Higgins JPT, Green S. Editors. Cochrane Handbook of Systematic Reviews of Interventions (Updated Sept 2006). Vol. 4.2.6, Oxford: The Cochrane Collaboration, 2006.
Hu 2003
    1. Hu TW, Wagner TH, Bentkover JD, Leblanc K, Piancentini A, Stewart WF, et al. Estimated economic costs of overactive bladder in the United States. Urology 2003;61:1123‐8. - PubMed
Hunsballe 2001
    1. Hunsballe JM, Djurhuus JC. Clinical options for imipramine in management of urinary incontinence. Urological Research 2001;29:118. - PubMed
ICI 2000
    1. Anonymous. Assessment and treatment of urinary incontinence. Scientific Commitee of the First International Consultation on Incontinence. Lancet 2000;355(9221):2153‐8. - PubMed
Kelleher 1997
    1. Kelleher CJ, Cardozo LD, Khullar V, Salvatore S. A new questionnaire to access the quality of life of urinary incontinent women. British Journal of Obstetrics & Gynaecology 1997;104:1374‐9. - PubMed
Kobelt 1997
    1. Kobelt G. Economic considerations and outcome measurement in urge incontinence. Urology 1997;50(6A suppl):100‐7. - PubMed
Lazzeri 1997
    1. Lazzeri M, Beneforti P, Turini D. Urodynamic effects of intravesical resiniferatoxin in humans: preliminary results in stable and unstable detrusor. Journal of Urology 1997;158:2093. - PubMed
Mattiasson A
    1. Mattiasson A, Ekstrom B, Andersson K‐E. Effects of intravesical instillation of verapamil in patients with detrusor hyperactivity. Journal of Urology 1989;141:174. - PubMed
Milsom 2001
    1. Milsom I, Abrams P, Cardozo L, Roberts RG, Thuroff J, Wein AJ. How widespread are the symptoms of an overactive bladder and how are they managed? A population‐based prevalence study. BJU International 2001;87(9):760‐6. - PubMed
Nabi 2006
    1. Nabi G, Cody JD, Ellis G, Herbison P, Hay‐Smith J. Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database of Systematic Reviews 2006, Issue 4. [Art. No.: CD003781. DOI: 10.1002/14651858.CD003781.pub2] - PMC - PubMed
Ouslander 1982
    1. Ouslander JG, Kane RL, Abrass IB. Urinary incontinence in elderly nursing home patients. Journal of the American Medical Association 1982;248(10):1194‐8. - PubMed
Ouslander 1986
    1. Ouslander JG, Hepps K, Raz S, Su HL. Genitourinary dysfunction in a geriatric outpatient population. Journal of the American Geriatrics Society 1986;34(7):507‐14. - PubMed
Stewart 2001
    1. Stewart WF, Herzog AR, Wein AJ, Abrams P, Payne C, Corey R, et al. Prevalence and impact of overactive bladder in the United States: Results from the NOBLE program. Neurology & Urodynamics 2001;20:403‐22.
Stewart 2003
    1. Stewart WF, Rooyen JB, Cundiff GW, Abrams P, Herzog AR, Corey R, et al. Prevalence and burden of overactive bladder in the United States. World Journal of Urology 2003;20(6):327‐36. - PubMed
Thuroff 1991
    1. Thuroff JW, Bunke B, Ebner A, Faber P, Geeter P, Hannappel J, et al. Randomized, double‐blind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin versus propantheline versus placebo. Journal of Urology 1991;145:813‐6. - PubMed
Van Kerrebroeck 1998
    1. Kerrebroeck PE, Amarenco G, Thuroff JW, Madersbacher HG, Lock MT, Messelink EJ, et al. Dose‐ranging study of tolterodine in patients with detrusor hyperreflexia. Neurourlogy & Urodynamics 1998;17(5):499‐512. - PubMed
Wallace 2004
    1. Wallace S, Roe B, Williams K, Palmer M. Bladder training for urinary incontinence in adults. Cochrane Database of Systematic Reviews 2004, Issue 1. [Art. No.: CD001308. DOI: 10.1002/14651858.CD001308.pub2] - PMC - PubMed
Wein 2001
    1. Wein AJ. Pharmacological agents for the treatment of urinary incontinence due to overactive bladder. Expert Opinion on Investigational Drugs 2001;10:65. - PubMed

MeSH terms